semaglutide hoboken Flex-Dose 1 mL Injectable 2.5 mg/mL Semaglutide: Next Generation Weight Loss

In the past, a watchful waiting approach was recommended in case the child grew out of having obesity, but more research has shown that this isn't as common as was thought

It was originally anticipated to end in mid-2024 but, as it is event-driven, the trial will only report when a predefined number of cardiovascular endpoints have occurred

Tate M, Robinson E, Green BD, et al

Curr Gene Ther

(2025, December 3)

The consequences of the cardiovascular disease-related reductions in CBF include accelerated reduction in frontal, parietal, and temporal grey matter volumes (Moroni et al., 2018), cognitive deficits (Jiang et al., 2023), and increased risk of ADRD (Brain et al., 2023)